ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Oncocyte Corp

Oncocyte Corp (0KCC)

51.00
0.00
( 0.00% )
Updated: 11:00:00

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
51.00
Bid
0.00
Offer
0.00
Volume
0.00
0.00 Day's Range 0.00
51.00 52 Week Range 51.00
Market Cap
Previous Close
51.00
Open
-
Last Trade
(O)
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
947
Shares Outstanding
8,261,000
Dividend Yield
-
PE Ratio
-0.59
Earnings Per Share (EPS)
-3.48
Revenue
7.27M
Net Profit
-28.72M

About Oncocyte Corp

Sector
In Vitro,in Vivo Diagnostics
Industry
In Vitro,in Vivo Diagnostics
Headquarters
Irvine, California, USA
Founded
-
Oncocyte Corp is listed in the In Vitro,in Vivo Diagnostics sector of the London Stock Exchange with ticker 0KCC. The last closing price for Oncocyte was US$51. Over the last year, Oncocyte shares have traded in a share price range of US$ 51.00 to US$ 51.00.

Oncocyte currently has 8,261,000 shares in issue. The market capitalisation of Oncocyte is US$421.31 million. Oncocyte has a price to earnings ratio (PE ratio) of -0.59.

0KCC Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1005151511151DE
400515151255651DE
120051515194751DE
260051515142451DE
520051515125551DE
1560051515115951DE
2600051515118951DE

0KCC - Frequently Asked Questions (FAQ)

What is the current Oncocyte share price?
The current share price of Oncocyte is US$ 51.00
How many Oncocyte shares are in issue?
Oncocyte has 8,261,000 shares in issue
What is the market cap of Oncocyte?
The market capitalisation of Oncocyte is USD 421.31M
What is the 1 year trading range for Oncocyte share price?
Oncocyte has traded in the range of US$ 51.00 to US$ 51.00 during the past year
What is the PE ratio of Oncocyte?
The price to earnings ratio of Oncocyte is -0.59
What is the cash to sales ratio of Oncocyte?
The cash to sales ratio of Oncocyte is 2.32
What is the reporting currency for Oncocyte?
Oncocyte reports financial results in USD
What is the latest annual turnover for Oncocyte?
The latest annual turnover of Oncocyte is USD 7.27M
What is the latest annual profit for Oncocyte?
The latest annual profit of Oncocyte is USD -28.72M
What is the registered address of Oncocyte?
The registered address for Oncocyte is 15 CUSHING, IRVINE, CALIFORNIA, 92618
What is the Oncocyte website address?
The website address for Oncocyte is www.oncocyte.com
Which industry sector does Oncocyte operate in?
Oncocyte operates in the IN VITRO,IN VIVO DIAGNOSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GENIGenincode Plc
5.25p
(64.06%)
20.47M
EMEEmpyrean Energy Plc
0.125p
(56.25%)
1.05B
WJGWatkin Jones Plc
24.75p
(24.75%)
12.11M
CLAICel Ai Plc
0.38p
(22.58%)
24.4M
MFAIMindflair Plc
1.25p
(19.05%)
84.68M
PPSProton Motor Power Systems Plc
0.175p
(-41.67%)
1.53M
ENWEnwell Energy Plc
17.50p
(-25.53%)
238.06k
QBTQuantum Blockchain Technologies Plc
1.185p
(-24.76%)
132.93M
MILAMila Resources Plc
0.175p
(-22.22%)
17.54M
REVBRevolution Beauty Group Plc
11.50p
(-18.56%)
7.29M
SYMESupply@me Capital Plc
0.0027p
(-8.47%)
1.31B
EMEEmpyrean Energy Plc
0.125p
(56.25%)
1.05B
NTVONativo Resources Plc
0.0021p
(5.00%)
862.02M
TRPTower Resources Plc
0.0275p
(-6.78%)
351.79M
MSMNMosman Oil And Gas Limited
0.025p
(-7.41%)
244.69M

Discussion

View Full Feed
stockprofitter stockprofitter 2 minutes ago
Yadda yadda yadda. It is a $33 IPO assuming warrants are exercised and 5X if they are not.
FNMA
sharky sharky 2 minutes ago
They have been keeping this one down too long here IMO. Revenues looking good for a trip. Accumulation picking up also.
ASII
JStewin JStewin 3 minutes ago
Is this rally driven by Trumps AI energy support? What is the target here?
OKLO
WilliamMunny WilliamMunny 3 minutes ago
BTW, a number of people here have indicated that Missling said the company was awaiting the finalization of the draft guidance before filing at the FDA. I actually don't recall him saying that, although I may not have been paying close enough attention at the time. Can anyone help me by pointing o
JPM
JTORENCE JTORENCE 3 minutes ago
Just telling it like it is SNOWFLAKE.
NWBO
crowin crowin 3 minutes ago
Yes give the SEC RDARS number!
RDAR
surfer44 surfer44 3 minutes ago
Paul & Linda McCartney — Uncle Albert/Admiral Halsey (Official)

https://youtu.be/zFxRKvxfCAw
GARYM1 GARYM1 3 minutes ago
I think the updates of the past are done as you can only state how great your product is and how big the market is so long and we are at that point in time.
They missed more then the first round of roll out.
SEV
La Flaca La Flaca 3 minutes ago
The point of the article is that trialists have relied on guidance from FDA, even "draft" guidance to design their trials. Anavex can do the same. I'm certain I can find examples of trialists relying on "draft guidances" (for trial designs) even those in which FDA sought comments. I think the conten
AVXL
doc2016 doc2016 4 minutes ago
kona, next question is when did samsung consider trying these quantum phenomenon apps/ai? did lg or interwoven have such?
IONQ
F14SVF24 F14SVF24 4 minutes ago
Another great straight up post NoMoDo. I thought about the Romans and their last stand. Like xkay. "Romans" hence the X symbol. But you got it. But HMBL is in a good position for the long haul.
HMBL
Saving Grace Saving Grace 4 minutes ago
Institutions loading heavily! Silver screen institutional buying large.
HYMC
vinnie1965 vinnie1965 4 minutes ago
SMH
TGLO
NoMoDo NoMoDo 4 minutes ago
This has been my beef. Us older people need clear instructions.However, it did not include the clear on-ramp and off-ramp for fiat currency.Good to hear that you liked the functionality.
HMBL
shamalamadingdong shamalamadingdong 4 minutes ago
Senator Cynthia Lummis is chair of the Senate Banking Subcommittee on Digital Assets, and CZ Reacts to Senator Cynthia Lummis' Appointment, Hints at U.S. Strategic Bitcoin Reserve.
https://www.binance.com/en/square/post/01-23-2025-cz-reacts-to-senator-cynthia-lummis-appointment-hints-at-u-s-s
BTCUSD
22rover 22rover 4 minutes ago
Let’s consider a scenario where there are 1,000 shareholders (that's a decent ballpark # for sc). At any given moment, it’s reasonable to expect around 1% of holders will decide to sell. This isn’t far-fetched at all. A portion of that 1% may go through a full-service broker—perhaps they use Schwab
SDCH
TrendTrade2016 TrendTrade2016 4 minutes ago
UPXI BLOWING UP OFF BOTTOM
UPXI
sammdogg1 sammdogg1 5 minutes ago
Hang on to your shares is great advice here. There's been downward pressure, and when there is we have always seen accompanying opinion as to why this company is finished. This time it's "slowing growth" or obstacles to growth. Stock prices aside, the one thing this company has always done is grow a
IDCC
Myth Myth 5 minutes ago
May 2015

Revised Form 10 to be Promptly Re-Filed with the S.E.C.
Dear HHSE Friends - As previously reported, HHSE was informed on April 28 that our prior auditor (Terry L. Johnson) had lost his authority to sign-off on Public Company audits. Accordingly, and without delay, HHS
HHSE
janetcanada janetcanada 5 minutes ago
👀***RDAR - A Good link....
***Email us at: Help@sec.gov
RDAR
branster branster 5 minutes ago
Investor082, of course after a big spike you will get a pullback, that is normal. But, you take a big risk of selling on the spike assuming big pullbacks are coming.
Approval is just the beginning not the end, approval opens the possibility door for all sorts of catalyst on the horizon. App
NWBO
Pro_v12001 Pro_v12001 6 minutes ago
Jabil took over Intel's Silicon photonics division. Lets partner with Jabil!

https://www.jabil.com/news/jabil-invests-future-ai-intel-silicon-photonics-transceiver.html
LWLG
eb0783 eb0783 6 minutes ago
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025.

https://investors.atossatherapeutics.com/news-releases/news-release-details/atossa-therapeutics-issues-letter-shareholders-highlighting-2024
ATOS
Getn otta det Getn otta det 6 minutes ago
You will oftentimes see gaps right around the earnings call. If the earnings beat expectations by a lot, then that most likely results in a runaway gap that may not ever get filled. That's not what's happened with us here. But imo it will just cycle lower to fill and then bounce higher, to a new
COOP